RxDoctor Payments DataLook up a doctor →

Kathleen Harris, MD

Internal Medicine · Longview, TXNPI 1407050008

Payments from drug & device makers

$3,077,421in general payments, 2019–2025

Across 3,414 payments — averaging $901.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$2.2M
  • Merck$698K
  • Boehringer Ingelheim International GmbH$104K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$35K
  • Novo Nordisk$956
  • Amgen$884
  • plus $5K from 40 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS2,794$2,233,749
Merck36$697,880
Boehringer Ingelheim International GmbH98$104,119
Boehringer Ingelheim Pharma GmbH & Co.kg7$34,840
Novo Nordisk66$956
Amgen(2 entities)95$884
AbbVie(2 entities)52$852
Pfizer30$556
AstraZeneca33$494
Bayer28$427
Novartis43$405
Lilly USA, LLC16$232
Amarin Pharma, Inc.11$214
Astellas Pharma US Inc9$214
Boehringer Ingelheim14$205
GSK12$194
Daiichi Sankyo Inc.10$189
Corcept Therapeutics3$82
Johnson & Johnson(2 entities)5$77
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$68
Abbott4$61
Xeris Pharmaceuticals, Inc.3$58
Kowa Pharmaceuticals America, Inc.4$51
Dynavax Technologies Corporation3$51
Phathom Pharmaceuticals, Inc.2$49
Eisai Inc.3$48
Exact Sciences3$48
Lundbeck LLC2$47
Sanofi-aventis U.S. LLC2$36
Radius Health, Inc.2$31
Arbor Pharmaceuticals, Inc.2$30
Esperion Therapeutics, Inc.2$30
Irhythm Technologies, Inc.1$29
Dexcom, Inc.1$24
Itamar Medical Inc1$21
Nevro Corp.1$20
Ultragenyx Pharmaceutical Inc.1$19
Madrigal Pharmaceuticals1$19
Mylan Specialty L.p.1$17
Abiomed1$17
E.r. Squibb & Sons, L.L.C.1$16
Axsome Therapeutics, Inc.1$15
Cashflow Solutions, LLC1$14
GE HealthCare1$12
Avanir Pharmaceuticals, Inc.1$12
Inogen, Inc.2$11

How this compares

$3,077,421 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$715,983
Medicare patients
785
Services billed
38,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Longview

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →